Premium
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody
Author(s) -
Monahan Paul E.,
Aledort Louis M.
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20204
Subject(s) - hemostasis , medicine , antibody , recombinant factor viia , hemostatic agent , titer , immunology , intensive care medicine
Achieving adequate hemostasis in patients with hemophilia and high‐titer inhibitor antibodies remains a challenge despite the development of plasma‐derived and recombinant therapies to bypass the inhibitory effect. A group of hemophilia treaters met to examine the factors that influence physician choices among the very costly and cumbersome available therapies. Specific knowledge deficits in need of prospective research were identified with respect to the rational treatment of inhibitor patients. Am. J. Hematol. 77:346–350, 2004. © 2004 Wiley‐Liss, Inc.